Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PHC Holdings Corporation (6523.T)
Tokyo, JP
PHC Holdings Corporation, through its network of subsidiaries, specializes in the innovation, production, and sale of medical instruments, advanced healthcare technology solutions, and life science merchandise. The company's product line includes blood glucose monitoring systems and a variety of other diagnostic and analytical tools, alongside sophisticated data integration platforms. It also delivers end-to-end anatomical pathology solutions, featuring specialized equipment, microscope slides, and diverse staining reagents. In the life sciences sector, PHC provides essential equipment and support services for sample preservation and cell culture. Furthermore, the company develops and deploys healthcare IT products, focusing on medical information systems designed for clinics and pharmacies dealing with health insurance. Its operations also extend to clinical testing, the manufacturing of diagnostic reagents, and providing support for pharmaceutical development. Established in 2014 and based in Tokyo, Japan, the company was formerly recognized as Panasonic Healthcare Holdings Co., Ltd. before officially changing its name to PHC Holdings Corporation in April 2018.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.52% | -4.07% | -7.90% | -5.20% | +0.00% | -14.27% | -0.31% | -29.83% | -63.52% | -63.52% | -63.52% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+0.8% Q1'26: +0.5% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-95.3% Q1'26: -107.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+8.4% Q1'26: +12.9% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+5.7% Q1'26: +4.9% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+3.5% ★ Q1'26: +3.1% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.3% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×4.92× Q1'26: 5.11× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 7 Rev. Ana. 4 EPS Ana. |
Mar 2027 7 Rev. Ana. 1 EPS Ana. |
Mar 2028 5 Rev. Ana. 5 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
340.45B
est: 338.22B (+0.7%)
|
356.43B
est: 351.59B (+1.4%)
|
353.90B
est: 357.76B (-1.1%)
|
361.59B
est: 361.32B (+0.1%)
|
364.53B
362.58B – 367.97B
+0.9% YoY
|
367.85B
364.10B – 372.06B
+0.9% YoY
|
374.96B
370.58B – 381.40B
+1.9% YoY
|
396.50B
392.16B – 402.19B
+5.7% YoY
|
409.70B
405.21B – 415.58B
+3.3% YoY
|
| EBITDA |
37.56B
est: 43.76B (-14.2%)
|
36.76B
est: 45.49B (-19.2%)
|
30.15B
est: 46.28B (-34.9%)
|
52.33B
est: 46.74B (+11.9%)
|
47.16B
46.91B – 47.60B
+0.9% YoY
|
47.59B
47.10B – 48.13B
+0.9% YoY
|
48.51B
47.94B – 49.34B
+1.9% YoY
|
51.30B
50.73B – 52.03B
+5.7% YoY
|
53.00B
52.42B – 53.76B
+3.3% YoY
|
| EBIT |
6.48B
est: 14.81B (-56.2%)
|
7.74B
est: 15.40B (-49.7%)
|
2.22B
est: 15.67B (-85.9%)
|
24.46B
est: 15.82B (+54.6%)
|
15.96B
15.88B – 16.11B
+0.9% YoY
|
16.11B
15.94B – 16.29B
+0.9% YoY
|
16.42B
16.23B – 16.70B
+1.9% YoY
|
17.36B
17.17B – 17.61B
+5.7% YoY
|
17.94B
17.74B – 18.20B
+3.3% YoY
|
| Net Income |
-8.46B
est: 13.40B (-163.1%)
|
-3.22B
est: 9.43B (-134.2%)
|
-12.89B
est: -12.87B (-0.2%)
|
10.48B
est: 11.32B (-7.4%)
|
5.16B
2.96B – 7.35B
-54.4% YoY
|
14.79B
14.77B – 15.26B
+187.0% YoY
|
16.70B
14.21B – 21.79B
+12.9% YoY
|
19.90B
19.76B – 20.42B
+19.2% YoY
|
21.76B
21.45B – 22.17B
+9.4% YoY
|
| SGA |
120.36B
est: 127.67B (-5.7%)
|
121.11B
est: 132.72B (-8.8%)
|
131.51B
est: 135.05B (-2.6%)
|
144.25B
est: 136.39B (+5.8%)
|
137.60B
136.87B – 138.90B
+0.9% YoY
|
138.86B
137.44B – 140.45B
+0.9% YoY
|
141.54B
139.89B – 143.97B
+1.9% YoY
|
149.67B
148.03B – 151.82B
+5.7% YoY
|
154.65B
152.96B – 156.87B
+3.3% YoY
|
| EPS |
-70.78
est: 105.57 (-167.0%)
|
-25.83
est: 74.10 (-134.9%)
|
-102.48
est: -102.15 (-0.3%)
|
83.13
est: 88.69 (-6.3%)
|
36.69
23.30 – 57.91
-58.6% YoY
|
118.01
116.33 – 120.21
+221.6% YoY
|
133.54
111.90 – 171.65
+13.2% YoY
|
157.90
155.65 – 160.85
+18.2% YoY
|
171.40
168.96 – 174.60
+8.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-01 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-15 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kyoko Deguchi | President, Chief Executive Officer & Chairman | 147M | female |
| Hideaki Takahashi | Corporate Officer | — | — |
| Kaiju Yamaguchi | Senior Executive Corporate Officer, Chief Financial Officer & Director | — | — |
| Kenichi Uchino | Corporate Officer | — | — |
| Makise | IR & Corporate Communications | — | — |
| Nobuaki Nakamura | Executive Corporate Officer and Head of Diagnostics & Life Sciences Domain | — | — |
| Peter Bodlund | Corporate Officer | — | — |
| Ryuichi Hirashima | Sr. Exec Corporate Officer, Chief Admin. Officer, Chief HR Officer & Chief Transformation Officer | — | — |
| Steven Lynum | Corporate Officer | — | — |
| Chikara Takauo | Corporate Officer | — | — |
| Takahide Watanabe | Corporate Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6523.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
